A research study comparing how well different doses of the medicine NNC0519-0130 lower blood sugar in people with type 2 diabetes

Investigation of the safety and efficacy of once weekly NNC0519-0130 in participants with type 2 diabetes- a dose finding study(NN9541-4945)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031230704

Enrollment

Registered

2024-03-15

Start date

2024-03-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

This is an interventional, 36-week, multi-national, multi-centre, randomised, 11 armed, dose-finding, phase 2 study. The study will be double-blinded within dose level of once weekly subcutaneously ad

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Diagnosed with type 2 diabetes mellitus >= 180 days before screening. - Stable daily dose(s) >=90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose: metformin with or without SGLT2 inhibitor. - HbA1c of 7.5-10.0% (58-86 mmol/mol) (both inclusive) as assessed by central laboratory at screening.

Exclusion criteria

Exclusion criteria: Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.

Design outcomes

Primary

Measure	Time frame
Change in HbA1c from baseline (week 0) to 12 weeks on a given maintenance dose (%-point)	—

Countries

Australia, Canada, India, Japan, Korea, South Africa, United States

Contacts

Public ContactAdministorator Clinical trail information

Novo Nordisk Pharma Ltd.

jphc_clinical_trials@novonordisk.com+81-362661000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026